Ditchcarbon
  • Contact
  1. Organizations
  2. GALAPAGOS
Public Profile
Pharmaceutical Preparation Manufacturing
US
updated 6 days ago

GALAPAGOS Sustainability Profile

Company website

GALAPAGOS NV, commonly referred to as Galapagos, is a pioneering biotechnology company headquartered in the United States, with significant operations in Europe. Founded in 1999, Galapagos has established itself in the pharmaceutical industry, focusing on the discovery and development of innovative medicines for various diseases, including inflammatory and fibrotic conditions. The company is renowned for its unique drug discovery platform, which leverages advanced technologies to identify and develop novel therapeutic candidates. Notable achievements include the successful development of several clinical-stage programmes, positioning Galapagos as a leader in the biopharmaceutical sector. With a commitment to scientific excellence and a robust pipeline, Galapagos continues to make significant strides in transforming patient care through groundbreaking therapies.

DitchCarbon Score

How does GALAPAGOS's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.

57

Industry Average

Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.

31

Industry Benchmark

GALAPAGOS's score of 57 is higher than 73% of the industry. This can give you a sense of how well the company is doing compared to its peers.

73%

Let us know if this data was useful to you

GALAPAGOS's reported carbon emissions

In 2024, GALAPAGOS reported total carbon emissions of approximately 48,655,000 kg CO2e. This figure includes 652,000 kg CO2e from Scope 1 emissions, 1,140,000 kg CO2e from Scope 2 emissions (market-based), and a significant 47,889,000 kg CO2e from Scope 3 emissions. The Scope 3 emissions breakdown reveals major contributions from purchased goods and services (39,116,000 kg CO2e) and capital goods (6,133,000 kg CO2e). In 2023, GALAPAGOS's total emissions were about 39,632,000 kg CO2e, with Scope 1 emissions at 2,922,000 kg CO2e, Scope 2 emissions (market-based) at 173,000 kg CO2e, and Scope 3 emissions reaching 36,537,000 kg CO2e. The largest component of Scope 3 emissions was also from purchased goods and services, amounting to 28,257,000 kg CO2e. The 2022 emissions data shows a total of approximately 76,062,000 kg CO2e, with Scope 1 emissions at 3,029,000 kg CO2e, Scope 2 emissions (market-based) at 218,000 kg CO2e, and Scope 3 emissions at 72,814,000 kg CO2e, again primarily driven by purchased goods and services (56,091,000 kg CO2e). Despite these figures, GALAPAGOS has not publicly committed to specific reduction targets or initiatives, as indicated by the absence of documented reduction targets or climate pledges. The emissions data is not cascaded from any parent organisation, ensuring that the reported figures are solely from GALAPAGOS NV. Overall, GALAPAGOS's emissions profile highlights a significant reliance on Scope 3 emissions, particularly from purchased goods and services, underscoring the need for comprehensive strategies to address their carbon footprint.

Unlock detailed emissions data

Access structured emissions data, company-specific emission factors, and source documents

202220232024
Scope 1
3,029,000
0,000,000
000,000
Scope 2
218,000
000,000
000,000
Scope 3
72,814,000
00,000,000
00,000,000

How Carbon Intensive is GALAPAGOS's Industry?

Very low
Low
Medium
High
Very high
Some industries are more carbon intensive than others. GALAPAGOS's primary industry is Pharmaceutical Preparation Manufacturing, which is very low in terms of carbon intensity compared to other industries.

How Carbon Intensive is GALAPAGOS's Location?

Very low
Low
Medium
High
Very high
The carbon intensity of the energy grid powering a company's primary operations has a strong influence on its overall carbon footprint. This request for GALAPAGOS is in US, which has a low grid carbon intensity relative to other regions.

GALAPAGOS's Scope 3 Categories Breakdown

GALAPAGOS's Scope 3 emissions, which increased by 31% last year and decreased by approximately 34% since 2022, demonstrating supply chain emissions tracking. Nearly all of their carbon footprint comes from suppliers and value chain emissions, representing nearly all emissions under the GHG Protocol, with "Purchased Goods and Services" being the largest emissions source at 82% of Scope 3 emissions.

Top Scope 3 Categories

2024
Purchased Goods and Services
82%
Capital Goods
13%
Business Travel
3%
Upstream Leased Assets
<1%
Fuel and Energy Related Activities
<1%
Employee Commuting
<1%
Waste Generated in Operations
<1%
End-of-Life Treatment of Sold Products
<1%
Upstream Transportation & Distribution
<1%
Downstream Transportation & Distribution
<1%

GALAPAGOS's Climate Goals (2030 & 2050)

Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.

GALAPAGOS has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.

Science Based Targets Initiative
Carbon Disclosure Project
The Climate Pledge
UN Global Compact
RE 100
Climate Action 100
Race To Net Zero
Reduction Actions

Compare GALAPAGOS's Emissions with Industry Peers

Roche Holding AG

CH
•
Pharmaceutical Preparation Manufacturing
Updated 10 days ago

Merck And Co

US
•
Pharmaceutical Preparation Manufacturing
Updated 2 days ago

Amgen

US
•
Pharmaceutical Preparation Manufacturing
Updated 7 days ago

Biogen

US
•
Pharmaceutical Preparation Manufacturing
Updated about 12 hours ago

Takeda

JP
•
Pharmaceutical Preparation Manufacturing
Updated about 8 hours ago

Eli Lilly and Company

GB
•
Pharmaceutical Preparation Manufacturing
Updated 1 day ago

Let us know if this data was useful to you

Where does DitchCarbon data come from?

Discover our data-driven methodology for measuring corporate climate action and benchmarking against industry peers

Ditchcarbon
v251030.3
[email protected]+44 203 475 7875Ditch Carbon Ltd167-169 Great Portland StreetLondon W1W 5PF
UL Solutions verification badge
CDP logo
Gartner Cool Vendor 2025 badge
ProductPortalScope 3 Tool FunctionalityDataIntegrationsPricing
CustomersHaleonGrant ThorntonHikmaRead all stories
SolutionsProcurement teamsSustainability teamsPlatform ownersCarbon accountants
ResourcesCalculation MethodologyDocumentationBlogFAQOrganizationsIndustriesSBTI APITrust CentreChangelog
AboutTeamCareersLicense AgreementPrivacy